摘要
为推进药物经济学评价应用于我国药品注册和药品报销,本文在研究澳大利亚药品注册现状及药品注册中关于药物经济学评价的规定基础上,合理借鉴其宝贵经验并建议:重视药物经济学在药品决策中的作用,并根据实际情况修订指导性指南,更新医保目录,逐步探索适合我国药物经济学评价的标准,更好地发挥其在决策过程中的应用。
Australia has a relatively complete drug registration process and pharmacoeconomics evaluation guidelines.In order to promote the application of pharmacoeconomic evaluation in drug registration and reimbursement in China,this paper introduces the current situation of drug registration in Australia and the regulations on pharmacoeconomic evaluation in drug registration,so as to draw on its valuable experience and provide suggests:We should pay attention to the role of pharmacoeconomics in drug decision-making,revise the guiding guidelines according to the actual situation,update the medical insurance catalog,and gradually explore the criteria suitable for pharmacoeconomics evaluation in China and improve its application in the decision-making process.
作者
苏霞
李惠军
孙鹤
SU Xia;LI Hui-jun;SUN He(Tianjin University,Tianjin 300072,China;Earnest&Yea-saying Med-Tech(Beijing)Co.,Ltd.,Beijing 100024,China;Tasly Academy,Tasly Holding Group Co.,Ltd.,Tianjin 300410,China;Tasly Group State Key Laboratory of Core Technology in Innovative Chinese Medicine Development,Tianjin 300410,China;Axeon Biomedicine Globalization Co.,Ltd.,Tianjin 300410,China)
出处
《中国合理用药探索》
2021年第7期10-14,共5页
Chinese Journal of Rational Drug Use
关键词
药物经济学
规范
药品注册
药品报销
建议
pharmacoeconomics
norms
drug registration
drug reimbursement
suggestion
